



Taipei International Breast Cancer Symposium 2023

台北國際乳癌研討會

Junichiro Watanabe

Topic:

Managing ER-Positive, HER2-Negative Advanced Breast Cancer, A Long Journey

Abstract:

Since eribulin methylate (HALAVEN[®]) improved overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC) in EMBRACE phase 3 study in 2012, improvement of patients' OS has been recognized as one of the significant goals in managing HER2-ABC. However, the life of HER2-ABC, especially estrogen receptor positive HRT2-ABC (ER+HER2-ABC) patients tend to be a long and bumpy road not only due to the disease but also the treatment itself.

Based on the background, the RESQ study, a prospective randomized trial, assesses the change in quality of life (QOL) during and after the HALAVEN[®] therapy compared with S1 (oral 5-FU derivative) had been conducted.

In the session, the various therapeutic effects of HALAVEN[®] including OS prolongation and improvement of QOL will be discussed.

References) #1 Coetes J (2011) Lancet, #2 Cortes J (2015) Breast Cancer Res Treat, #3 Miyoshi Y (2020) Breast Cancer, #4 Watanabe J (2021) Breast Cancer Res Treat